Quote this publication Share Print

DELTYBA (delamanid), antituberculosis agent

INFECTIOLOGY - New medicinal product
Opinions on drugs - Posted on Apr 06 2016

Reason for request


Moderate improvement in combination with other antituberculosis agents in the treatment of multidrug-resistant pulmonary tuberculosis


  • DELTYBA has Marketing Authorisation in multidrug-resistant pulmonary tuberculosis in combination with other antituberculosis agents.
  • The evidence for its efficacy is based on very limited data.
  • Its safety profile appears favourable; the only important risk, that has been identified, isprolongation of the QT interval, which can be problematic if used in combination with other drugs that prolong the QT.
  • The WHO and the French High Council for Public Health (HCSP) have included it in the strategy for treating multidrug resistant tuberculosis with a combination of more than one antituberculosis drug chosen in accordance with in-vitro resistance, contraindications and intolerance risks.
  • DELTYBA must be prescribed by doctors experienced in the treatment of multidrug resistant tuberculosis, with the choice of treatment protocol based on the recommendations of an expert panel (e.g. CNR-MyRMA [French National Reference Centre for Mycobacteria and Mycobacteria Resistance to Antituberculosis Agents]).

Clinical Benefit



Clinical Added Value



Therapeutic use


Contact Us

Évaluation des médicaments